about
Primary care management of early stage chronic lymphocytic leukaemia is safe and effectiveT-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice.Cytomegalovirus viral load within blood increases markedly in healthy people over the age of 70 years.Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemiaNK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma.Monoclonal gammopathy of undetermined significance: an update for nephrologists.USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants.Metabolic plasticity in CLL: adaptation to the hypoxic niche.Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts.Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma.Effect of the UK postcode lottery on survival of patients with metastatic renal cancer: an audit of outcomes in patients with metastatic renal cancer suitable for treatment with tyrosine kinase inhibitors.A disease-linked ULBP6 polymorphism inhibits NKG2D-mediated target cell killing by enhancing the stability of NKG2D ligand binding.ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.The number of cytomegalovirus-specific CD4+ T cells is markedly expanded in patients with B-cell chronic lymphocytic leukemia and determines the total CD4+ T-cell repertoire.Poor functional antibody responses are present in nearly all patients with chronic lymphocytic leukaemia, irrespective of total IgG concentration, and are associated with increased risk of infectionAssessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK inhibition as an Effective Strategy
P50
Q36103295-C387B0A6-41A4-4048-8704-6197477928A7Q36245171-17959909-3080-4A81-97C3-C55F721969EBQ36428456-732F4FE3-B3FF-46F5-9DF6-9F7B5D887896Q37118775-4BFDB491-2F0B-432B-8C58-1B2595FBA2D5Q37708827-9254D11E-F0B7-4701-AE99-664B8C58F455Q38037704-C8F05C12-0E80-4C28-BC46-DD8D074F9DEEQ38703821-1763EDE8-A455-4137-8ACC-B6DE26309EB1Q40972934-41A27FA5-F142-4C20-870F-CC46EDED450EQ41094283-42AD5A2E-540C-422C-BE74-FCC8983F24C8Q41280348-DABC81C4-66FB-4096-8C30-17C75F1AD264Q42577801-1B9390A6-90BA-46CA-A549-459436D6A907Q43288696-029FEB9D-766F-454D-9D76-693C92755052Q47074393-D0F493EC-A2FB-4DDA-9C1E-3B16118DAD80Q50913049-61DA9B9A-E48A-46DC-A0F1-826C77B48A88Q51049227-C87E020C-EA06-4F3C-B1A9-7CD6E1AB4F16Q87205950-87C97487-5C18-4B29-A6B4-961BC172C863Q90538040-91C882F0-36D4-413F-966B-AE31DE6DD147
P50
description
researcher, ORCID id # 0000-0002-9707-8167
@en
wetenschapper
@nl
name
H Parry
@ast
H Parry
@en
H Parry
@nl
type
label
H Parry
@ast
H Parry
@en
H Parry
@nl
prefLabel
H Parry
@ast
H Parry
@en
H Parry
@nl
P106
P31
P496
0000-0002-9707-8167